Turn Therapeutics Inc.
NASDAQ:TTRXBiotechnology
-$0.17 today
- Market cap
- $271.79M
- Beta
- 2.77
- P/E (TTM)
- -45.0
- EPS (TTM)
- -$0.13
Volume 0.05M
Average 0.04M
TTRX Total Current Liabilities
All obligations due within one year.
Turn Therapeutics Inc.NASDAQ: TTRX
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities of $5.13M in Q1 FY2026
Q1 FY2026 total current liabilities was $5.13M.
Context
- Total current liabilities amounted to 27.5% of total assets at the end of Q1 FY2026.
- Total current liabilities increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 6M USD
- Year-over-year change
- +748.0%
- 2-year CAGR
- +250.1%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6M | +748.0% |
| FY2024 | 2024-12-31 | 707.93K | +44.5% |
| FY2023 | 2023-12-31 | 489.78K | — |
Total Current Liabilities vs competitors
How TTRX compares with its peers on the latest reported figures
- TTRX's Mar 2026 total current liabilities of $5.13M is the 8th highest of the 9 companies compared; the peer median is $6.06M.
- Total current liabilities amounts to 27.5% of total assets for TTRX, versus a peer median of 15.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $249.24M | +19.7% | +19.6% | 133.7% | |
| Mar 2026 | $10.24M | -22.4% | +7.6% | 3.8% | |
IRDOpus Genetics, Inc. | Mar 2026 | $9.34M | -61.5% | +41.4% | 14.0% |
| Mar 2026 | $6.07M | +26.9% | +27.3% | 20.4% | |
| Mar 2026 | $6.05M | -44.7% | +21.3% | 16.7% | |
| Mar 2026 | $5.71M | -33.2% | +31.0% | 3.3% | |
| Mar 2026 | $5.24M | +263.9% | +180.9% | 49.8% | |
TTRXTurn Therapeutics Inc. | Mar 2026 | $5.13M | — | — | 27.5% |
| Apr 2026 | $1.5M | -20.5% | -1.2% | 10.1% | |
| Peer median (excluding TTRX) | $6.06M | -21.4% | +24.3% | 15.4% | |
Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Turn Therapeutics Inc.
NASDAQ:TTRX
Intrinsic Alpha fair value
Locked
Current Price
$8.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.